

## SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB) INDEX 2023

Fresenius Group compiles and discloses data based on the metrics of the Sustainability Accounting Standards Board (SASB) in its Index 2023. Going forward, we continuously strive to improve our disclosure of quantitative metrics and further enhance our SASB reporting. With this process, we are acknowledging the importance of the SASB standard among our investors.

In the 2023 reporting year, we used the SASB standards updated in 2023. These will officially replace the standards last updated in 2018 as of 2025, but are already available for implementation. Our disclosures are based on the Sustainable Industry Classification System (SICS) industries within the health industry sector, with a focus on those sectors that best reflect our different business fields: Biotechnology & Pharmaceuticals (BP), Health Care Delivery (DY), Health Care Distributors (DI), and Medical Equipment & Supplies (MS). Due to the diversified business model of Fresenius SE & Co. KGaA and its subsidiaries, only those indicators of the identified industry standards which are relevant for our operations are included in the index provided.

The majority of references within this index refer to the Fresenius 2023 Group Annual Report (see: [https://annualreport.fresenius.com/wp-content/uploads/sites/12/2024/02/Fresenius\\_Annual\\_Report\\_2023.pdf](https://annualreport.fresenius.com/wp-content/uploads/sites/12/2024/02/Fresenius_Annual_Report_2023.pdf)), including the Fresenius 2023 Separate Group Non-financial Report (see pages 102 ff. of the Group Annual Report 2023).

Unless otherwise stated, all reported data are as of December 31, 2023.

Topic	Code	Accounting metric	Comment and link
<b>Biotechnology &amp; Pharmaceuticals</b>			
<b>Safety of Clinical Trial Participants</b>	HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	<p>Fresenius Group reports on the management approach with regard to clinical trials and clinical study management as well as on its organization and relevant guidelines or policies. Information provided focuses on clinical studies in pharmaceutical approval processes in our healthcare products market segment and innovative treatment concepts in the healthcare services market segment. It is ensured that scientific, ethical and legal requirements are met. Only studies with an existing ethical vote and in compliance with all patients' rights are carried out. Detailed information is provided to a patient who decides to participate in a study by specially trained and dedicated staff. Patients are free to decide whether or not to participate.</p> <p>Fresenius Group Non-financial Report 2023: Innovation &gt; Our approach &gt; Product innovation &gt; <b>Clinical studies in pharmaceutical approval processes</b> (pg. 133 f.) &gt; <b>Innovative treatment concepts</b> (pg. 135 f.)</p> <p><b>Caring for Human Rights:</b> <a href="https://www.fresenius.com/human-rights">https://www.fresenius.com/human-rights</a></p>
	HC-BP-210a.2	Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	<p>Fresenius Group reports on the management approach with regard to clinical trials and clinical study management as well as on its organization and relevant guidelines or policies. Information is provided for all business segments with a focus on clinical study management in our hospitals. It is ensured that scientific, ethical and legal requirements are met. Only studies with an existing ethical vote and in compliance with all patients' rights are carried out. Detailed information is provided to a patient who decides to participate in a study by specially trained and dedicated staff. Patients are free to decide whether or not to participate. Inspections conducted by external bodies are not published separately. At Fresenius Kabi, the total number of inspections in the reporting year is provided.</p> <p>Fresenius Group Non-financial Report 2023: Well-being of the patient &gt; Patient and product safety &gt; Our approach &gt; Healthcare products market segment: Fresenius Kabi &gt; Guidelines and regulations: <b>Table "Audits and inspections"</b> (pg. 123)</p>
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	All relevant legal proceedings and related financial affects are disclosed in our Fresenius Group Annual Report 2023 - Note 31: <b>Commitments and contingencies</b> (pg. 327 f.)

<b>Access to Medicines</b>	HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Fresenius Group Non-financial Report 2023: Well being of patients > <b>Access to healthcare and medicine</b> (pg. 116) > Access to healthcare and medicine > <b>Our approach</b> (S.116 f.) > Access to healthcare and medicine > <b>Patient support in crisis and emergency situations</b> (S. 118)  <b>Cooperation and social activities 2023:</b> <a href="https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/">https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/</a>
	HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Fresenius Kabi has one entity mentioned as API manufacturing site for two listed products on the WHO List of Prequalified Medicinal Products as of the reporting year 2023. For more information, click here: <a href="https://extranet.who.int/prequal/medicines/ha479">https://extranet.who.int/prequal/medicines/ha479</a> <a href="https://extranet.who.int/prequal/medicines/ha480">https://extranet.who.int/prequal/medicines/ha480</a>
<b>Drug Safety</b>	HC-BP-250a.1	Products listed in public medical product safety or adverse event alert databases	Fresenius Group Non-financial Report 2023: Well being of patients > Patient and product safety > Healthcare products market segment: Fresenius Kabi > <b>Product risk management</b> (pg. 124)  Please refer to MedWatch: The FDA Safety Information and Adverse Event Reporting Program: <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program</a>
	HC-BP-250a.2	Number of fatalities associated with products	Fresenius Group Non-financial Report 2023: Well-being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi > <b>Guidelines and regulations</b> (pg. 122 f.) > <b>Monitoring and reporting systems</b> (pg. 123 f.)
	HC-BP-250a.3	(1) Number of recalls issued, (2) total units recalled	Fresenius Group does not report on the numbers of recalls or total units recalled. It is our aim to act fast and proactively concerning recall execution in order to minimize potential risks for patients. The recalls are discussed and agreed on beforehand in cooperation with the respective authority. For information on our approach towards recalls, see:  Fresenius Group Non-financial Report 2023: Well being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi > <b>Product risk management</b> (pg. 124)
	HC-BP-250a.5/ HC-MS-250a.4	Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type	We report on inspections and enforcement actions taken, if material for the operating business, in our quarterly and annual reports.  Fresenius Group Annual Report 2023: <b>Significant characteristics of the Fresenius risk management system and entire internal control system</b> (pg. 87 f.)  Fresenius Group Non-financial Report 2023: Well being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi > Guidelines and regulations (pg. 123): <b>Table "Audits and inspections"</b>
<b>Counterfeit Drugs</b>	HC-BP-260a.1/ HC-DI-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	Fresenius Group Non-financial Report 2023: > Well being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi > <b>Labeling and product information</b> (pg. 124); > Digital transformation > Our approach > <b>Digital processes and applications</b> (pg. 139 ff.)  Fresenius Kabi Drug Supply Chain Security Act (DSCSA): <a href="https://www.fresenius-kabi.com/us/drug-supply-chain-security-act-dscsa">https://www.fresenius-kabi.com/us/drug-supply-chain-security-act-dscsa</a>
<b>Ethical Marketing</b>	HC-BP-270a.1/ HC-MS-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: <b>Commitments and contingencies</b> (pg. 327 f.)

	HC-BP-270a.2/ HC-MS-270a.2	Description of code of ethics governing promotion of off-label use of products	<p><b>Fresenius Kabi:</b> <a href="https://www.fresenius-kabi.com/us/documents/Code-of-Conduct-Fresenius-Kabi-USA.pdf">https://www.fresenius-kabi.com/us/documents/Code-of-Conduct-Fresenius-Kabi-USA.pdf</a></p> <p>Fresenius Group Non-financial Report 2023: Well being of the patient &gt; Patient and product safety &gt; Healthcare products market segment &gt; <b>Labeling and product information</b> (pg. 124)</p>
<b>Employee Recruitment, Development &amp; Retention</b>	HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	<p>We place special importance on those employees, who support our ambitions on innovative treatment concepts and product innovations. For overarching measures, please see:</p> <p>Fresenius Group Non-financial Report 2023: <b>Innovation</b> (pg. 132 ff.) Employees &gt; Our approach &gt; <b>Recruitment</b> (pg. 149 f.) &gt; <b>Employee development</b> (pg. 150 ff.) &gt; <b>Employee retention</b> (pg. 152)</p>
	HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	<p>Fresenius discloses the voluntary turnover for each business segment and for the Group per region, but not as a break-down for management levels. We aim to improve the reporting scope on recruitment data going forward and assess internally to add further KPIs for this aspect.</p> <p>Fresenius Group Non-financial Report 2023: Employees &gt; Our approach &gt; <b>Employee retention</b> (pg. 152)</p> <p><b>Voluntary turnover by region</b> (reporting started in 2021): ESG KPI Overview: <a href="https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/">https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/</a></p>
<b>Business Ethics</b>	HC-BP-510a.1/ HC-DI-510a.2/ HC-MS-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	<p>All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: <b>Commitments and contingencies</b> (pg. 327 f.)</p>
	HC-BP-510a.2/ HC-MS-510a.2	Description of code of ethics governing interactions with health care professionals	<p>Fresenius Group Non-financial Report 2023: &gt; Strategy and management &gt; Stakeholders and partnerships &gt; <b>Transparency in the healthcare sector</b> (pg. 111) &gt; Well being of the patient &gt; Patient and product safety &gt; Healthcare products market segment: Fresenius Kabi &gt; <b>Labeling and product information</b> (pg. 124) &gt; Compliance and integrity &gt; Compliance &gt; Our approach &gt; <b>Guidelines and regulations</b> (pg. 171 f.)</p> <p><b>Fresenius Group Compliance:</b> <a href="https://www.fresenius.com/compliance">https://www.fresenius.com/compliance</a></p>
<b>Activity metrics</b>	HC-BP-000.A	Number of patients treated	<p>Fresenius Group Non-financial Report 2023: Well being of the patient &gt; Patient and product safety &gt; Healthcare services market segment: Fresenius Helios &gt; <b>Treatment quality</b> (pg. 126)</p>
	HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	<p>Please refer to our Capital Markets Day 2023: <a href="https://www.fresenius.com/sites/default/files/2023-05/Fresenius_CMD_2023_Presentation_0.pdf">https://www.fresenius.com/sites/default/files/2023-05/Fresenius_CMD_2023_Presentation_0.pdf</a></p>

Health Care Delivery			
<b>Energy Management</b>	HC-DY-130a.1	(1) Total energy consumed, (2) percentage grid electricity, (3) percentage renewable	<p>Fresenius Group Non-financial Report 2023: Environment &gt; Climate protection - energy and emissions &gt; Our approach &gt; Energy Consumption (pg. 192 ff)</p> <p>(1) Conversion: Fresenius Group reports the total energy consumption in MWh. Converted into GJ, Fresenius Group consumed 11,124,000 GJ in 2023 (3.09 million MWh).                      (2) 38.07%                      (3) 21% of total energy consumption (18% electricity (renewable), 3% renewable fuels)</p>
<b>Waste Management</b>	HC-DY-150a.2	Total amount of: (1) hazardous and (2) non-hazardous pharmaceutical waste, percentage (a) incinerated, (b) recycled or treated and (c) landfilled	<p>We are providing information on hazardous and non-hazardous waste (Fresenius Kabi and Fresenius Helios), and on waste in relation to hospital beds (Fresenius Helios) in our ESG KPI Overview: <a href="https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/">https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/</a></p> <p>Fresenius Separate Group Non-financial Report 2023: Environment &gt; <b>Waste and recycling management</b> (pg. 189 f.)</p>
<b>Patient Privacy &amp; Electronic Health Records</b>	HC-DY-230a.2	Description of policies and practices to secure customers' personal health data records and other personal data	<p>Fresenius Group Non-financial Report 2023:                      &gt; Strategy and management &gt; Stakeholders and partnerships &gt; Stakeholder dialog in all areas &gt; <b>Transparency in the healthcare sector</b> (pg. 111)                      &gt; Compliance and Integrity &gt; <b>Data protection</b> (pg. 176 ff.)</p>
	HC-DY-230a.3	(1) Number of data breaches, (2) percentage involving (a) personal data only and (b) personal health data, (3) number of customers affected in each category, (a) personal data only and (b) personal health data	<p>Fresenius Group Non-financial Report 2023: Compliance and Integrity                      &gt; Compliance &gt; Our approach &gt; Organization and responsibilities &gt; <b>Reporting paths</b> (pg. 170 f.)                      &gt; Data protection &gt; <b>Reporting systems</b> (pg. 177)</p>
	HC-DY-230a.4	Total amount of monetary losses as a result of legal proceedings associated with data security and privacy	<p>All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: <b>Commitments and contingencies</b> (pg. 327 f.)</p>
<b>Quality of Care &amp; Patient Satisfaction</b>	HC-DY-250a.2	Number of serious reportable events	<p>Fresenius Group reports on serious reportable events with regard to treatments in hospitals and healthcare facilities (Fresenius Helios). We provide information both on serious events as well as critical incidents in our Fresenius Group Non-financial Report 2023.</p> <p>Fresenius Group Non-financial Report 2023: Well being of the patient &gt; Patient and product safety &gt; Healthcare services market segment: Fresenius Helios &gt; Treatment quality &gt; <b>Patient safety and reporting systems</b> (pg. 127 f.)</p>
	HC-DY-250a.3	Hospital-acquired condition rates per hospital	<p>The Hospital-Acquired Condition rate is not calculated for hospitals and healthcare facilities in the business segments Fresenius Helios and Fresenius Vamed. However, we report on indicators in our hospitals and healthcare facilities which are comparable to those of the HAC Score, please refer to: <a href="https://www.helios-gesundheit.de/qualitaet/erregger/">https://www.helios-gesundheit.de/qualitaet/erregger/</a></p> <p>Fresenius Group Non-financial Report 2023: Well being of the patient &gt; <b>Patient and product safety</b> (pg. 118 ff)</p>

<b>Management of Controlled Substances</b>	HC-DY-260a.1	Description of policies and practices to manage the number of prescriptions issued for controlled substances	<p>Hygiene management at Fresenius Helios focuses on close monitoring of infections and pathogens, regular hygiene training for hospital staff, for example on correct hand disinfection, <b>monitoring antibiotic consumption</b>, and training physicians as <b>antibiotic stewardship (ABS) specialists</b>. The implementation of and compliance with hospital hygiene measures in the clinics is accompanied and monitored by our specially trained staff – e. g., hygiene specialist nurses, hospital hygienists, and hygiene officers. The Helios Group hygiene regulation is binding for all employees in all clinics of Helios Germany. It is based on the evidence-based recommendations of the Robert Koch Institute (RKI) and prescribes, among other things, hand disinfection – especially before and after contact with patients – for physicians, nurses, medical staff, and other personnel, in accordance with the guidelines of the WHO. Anomalies in consumption are recorded in targeted reviews. In this way, developments can be closely observed and analysed.</p> <p>Fresenius Group Non-financial Report 2023: Well being of the patient &gt; Patient and product safety &gt; Healthcare services market segment: Fresenius Helios &gt; <b>Hygiene management in hospitals</b> (pg. 128)</p> <p>List of antibiotics and amount per antibiotic used in treatments overall and per clinic in Germany of Fresenius Helios: <a href="https://www.helios-gesundheit.de/qualitaet/antibiotika/">https://www.helios-gesundheit.de/qualitaet/antibiotika/</a> (available in German language only)</p>
<b>Workforce Health &amp; Safety</b>	HC-DY-320a.1	Total recordable incident rate (TRIR) for (a) direct employees and (b) contract employees	<p>We disclose the lost time injury frequency rate (LTIFR) for Fresenius Kabi, Fresenius Helios in Spain and Fresenius Vamed. Fresenius Helios Germany is currently implementing the LTIFR.</p> <p>Fresenius Group Non-financial Report 2023: Occupational health and safety &gt; <b>Other work-related accidents and incidents</b> (pg. 159)</p>
<b>Employee Recruitment, Development &amp; Retention</b>	HC-DY-330a.1	(1) Voluntary and (2) involuntary turnover rate for: (a) physicians, (b) non-physician health care practitioners, and (c) all other employees	<p>We do not provide a split for physicians, non-physician healthcare practitioners but only for all employees in a business segment. However, the majority of employees are nurses and medical staff.</p> <p>Fresenius Group Non-financial Report 2023: Employees &gt; Our approach &gt; <b>Employee retention</b> (pg. 152 f.)</p>
	HC-DY-330a.2	Description of talent recruitment and retention efforts for health care practitioners	<p>Fresenius Group Non-financial Report 2023: Employees &gt; Our approach &gt; <b>Employee development</b> (pg. 150 ff.) &gt; <b>Employee retention</b> (pg. 152)</p>
<b>Climate Change Impacts on Human Health &amp; Infrastructure</b>	HC-DY-450a.1	Description of policies and practices to address: (1) the physical risks because of an increased frequency and intensity of extreme weather events, (2) changes in the morbidity and mortality rates of illnesses and diseases associated with climate change and (3) emergency preparedness and response	<p>Fresenius Group is currently assessing the impacts of climate change on our operating business. In the future, we will assess the impact of Scope 3 emissions to include them in our targets as well. We will provide updates on these assessments in our non-financial reporting going forward.</p> <p>Fresenius Group Non-financial Report 2023: Strategy and management &gt; <b>Sustainability risks and controls</b> (pg. 106 f.) &gt; <b>Our sustainability goals and programs</b> (pg. 107) &gt; <b>EU-Taxonomy</b> (pg. 111 ff.) Well being of patients &gt; Access to healthcare and medicine &gt; <b>Patient support in crisis and emergency situations</b> (pg. 118) Environment &gt; Environmental management &gt; Our approach &gt; <b>Identification and management of environmental risks</b> (pg. 186) &gt; <b>Climate protection – energy and emissions</b> (pg. 190 ff.)</p>
<b>Fraud &amp; Unnecessary Procedures</b>	HC-DY-510a.1	Total amount of monetary losses as a result of legal proceedings associated with medical fraud	<p>All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: <b>Commitments and contingencies</b> (pg. 327 f.)</p>

<b>Activity metrics</b>	HC-DY-000.A	Number of (1) facilities and (2) beds, by type	<b>ESG KPI Overview:</b> <a href="https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/">https://annualreport.fresenius.com/2023/non-financial-report/further-information/esg-kpis-and-standards/</a>
	HC-DY-000.B	Number of (1) inpatient admissions and (2) outpatient visits	Fresenius Group Non-financial Report 2023: Well-being of the patient > Patient and product safety > Healthcare services market segment: Fresenius Helios > <b>Treatment quality</b> (pg. 126)
<b>Health Care Distributors</b>			
<b>Product Safety</b>	HC-DI-250a.1	Total amount of monetary losses as a result of legal proceedings associated with product safety	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: <b>Commitments and contingencies</b> (pg. 327 f.)
	HC-DI-250a.2	Description of efforts to minimize health and safety risks of products sold associated with toxicity/chemical safety, high abuse potential, or delivery	Fresenius Group Annual Report 2023: Opportunities and risk report > <b>Significant characteristics of the Fresenius risk management system and entire internal control system</b> (pg. 87 f.)  Fresenius Group Non-financial Report 2023: Well being of the patient > <b>Patient and product safety</b> (pg. 118 f.)
<b>Counterfeit Drugs</b>	HC-DI-260a.1/ HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the distribution chain and prevent counterfeiting	see HC-BP-260a.1
	HC-DI-260a.2	Discussion of due diligence process to qualify suppliers of drug products and medical equipment and devices	Suppliers related to product manufacturing are subject to qualification processes based on the relevance of the delivered material or service. In the healthcare products market segment, the supplier's qualification and their recertification is regularly audited.  Fresenius Group Non-financial Report 2023: > Well-being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi > <b>Guidelines and regulations</b> (pg. 122 f.) > Compliance and Integrity > Human rights > <b>Supplier evaluation</b> (pg. 183)
	HC-DI-260a.3	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	Fresenius Group Non-financial Report 2023: Well-being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi > <b>Product risk management</b> (pg. 124)  Fresenius Kabi - Pharmaceutical Products: <a href="https://www.fresenius-kabi.com/us/pharmaceutical-products">https://www.fresenius-kabi.com/us/pharmaceutical-products</a>
<b>Business Ethics</b>	HC-DI-510a.1	Description of efforts to minimize conflicts of interest and unethical business practices	Fresenius Group Non-financial Report 2023: <b>Compliance and integrity</b> (pg. 169 ff.)  Fresenius Group Annual Report 2023: Corporate Governance > Corporate Governance Declaration > <b>Independence and conflicts of interest</b> (pg. 209)
	HC-DI-510a.2	Total amount of monetary losses as a result of legal proceedings associated with bribery, corruption, or other unethical business practices	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: <b>Commitments and contingencies</b> (pg. 327 f.)

<b>Activity metrics</b>	HC-DI-000.A	Number of pharmaceutical units sold by product category	We do not disclose the number of pharmaceutical units sold by product category, only sales by product segment.  #FutureFresenius – Advancing Patient Care: <a href="https://www.fresenius.com/sites/default/files/2024-02/Fresenius_FY_2023_4.pdf">https://www.fresenius.com/sites/default/files/2024-02/Fresenius_FY_2023_4.pdf</a> (pg. 36)
	HC-DI-000.B	Number of medical devices sold by product category	We do not disclose the number of medical devices sold by product category, only sales by product segment.  #FutureFresenius – Advancing Patient Care: <a href="https://www.fresenius.com/sites/default/files/2024-02/Fresenius_FY_2023_4.pdf">https://www.fresenius.com/sites/default/files/2024-02/Fresenius_FY_2023_4.pdf</a> (pg. 36)
<b>Medical Equipment &amp; Supplies</b>			
<b>Product Safety</b>	HC-MS-250a.1	(1) Number of recalls issued, (2) total units recalled	Fresenius Group does not report on the total numbers of recalls or total units recalled. It is our aim to act fast and proactively concerning recall execution in order to minimize potential risks for patients. The recalls are discussed and agreed on beforehand with the respective authority.  Fresenius Group Non-financial Report 2023: Well being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi > <b>Product risk management</b> (pg. 124)  Example: Fresenius Kabi - Pharmaceutical Products <a href="https://www.fresenius-kabi.com/us/pharmaceutical-products">https://www.fresenius-kabi.com/us/pharmaceutical-products</a> <a href="https://www.fresenius-kabi.com/us/pharmaceutical-product-updates">https://www.fresenius-kabi.com/us/pharmaceutical-product-updates</a>  See: <a href="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts?search_api_fulltext=Fresenius&amp;field_regulated_product_field=All">https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts?search_api_fulltext=Fresenius&amp;field_regulated_product_field=All</a>
	HC-MS-250a.2	Products listed in any public medical product safety or adverse event alert database	Please refer to the FDA Adverse Event Reporting: <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program</a>  Fresenius Group Non-financial Report 2023: Well being of the patient > Patient and product safety > Healthcare products market segment : Fresenius Kabi > <b>Product risk management</b> (pg. 124)
	HC-MS-250a.4	Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type	In the reporting year, there were no actions taken that stand against our quality goals. Guidelines of Good Manufacturing Practice (GMP) and current Good Manufacturing Practice (cGMP) guidelines are taken into account, see:  Fresenius Group Non-financial Report 2023: Well-being of the patient > Patient and product safety > Healthcare products market segment: Fresenius Kabi > <b>Guidelines and regulations</b> (pg. 122 f.)
<b>Ethical Marketing</b>	HC-MS-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	All relevant legal proceedings and related financial affects are disclosed in our Fresenius 2023 Group Annual Report - Note 31: <b>Commitments and contingencies</b> (pg. 327 f.)
	HC-MS-270a.2	Description of code of ethics governing promotion of off-label use of products	We provide information in the codes of ethics and conduct of our business segments governing promotion of off-label use of products, if applicable.  Example: Fresenius Kabi USA: <a href="https://www.fresenius-kabi.com/us/documents/Code-of-Conduct-Fresenius-Kabi-USA.pdf">https://www.fresenius-kabi.com/us/documents/Code-of-Conduct-Fresenius-Kabi-USA.pdf</a>

<b>Product Design &amp; Lifecycle Management</b>	HC-MS-410a.2	Total amount of products accepted for takeback and reused, recycled, or donated, broken down by: (1) devices and equipment and (2) supplies	In the health sector, the takeback, reuse and recycling of our products and materials is regulated on national level. Fresenius Group does not report on the total amount of products accepted for takeback and reused, recycled, or donated.
<b>Supply Chain Management</b>	HC-MS-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in third-party audit programs for manufacturing and product quality	Fresenius Group aims to improve the reporting scope on supply chain going forward.  Fresenius Group Non-financial Report 2023: Compliance and Integrity > Human rights > <b>Supplier evaluation</b> (pg. 183)
	HC-MS-430a.2	Description of efforts to maintain traceability within the distribution chain	Fresenius Kabi - Drug supply chain security act: <a href="https://www.fresenius-kabi.com/us/drug-supply-chain-security-act-dscsa">https://www.fresenius-kabi.com/us/drug-supply-chain-security-act-dscsa</a>  Fresenius Group Non-financial Report 2023: Compliance and integrity > Human rights > <b>Supplier evaluation</b> (pg. 183)
	HC-MS-430a.3	Description of the management of risks associated with the use of critical materials	Before the EU Conflict Minerals Regulation came into force, Fresenius SE & Co. KGaA and its operating units already addressed this sensitive issue. We do not purchase conflict minerals directly. However, it cannot be completely ruled out that they have been processed in components and semifinished products that we purchase and further process or use in our products. In this case, our purchasing guidelines apply, as do the relevant Group and business segment codes of conduct for dealing with suppliers and other business partners.  Fresenius Group Non-financial Report 2023: Compliance and integrity > <b>Human rights</b> (pg. 179 ff.)
<b>Business Ethics</b>	HC-MS-510a.1/ HC-BP-510a.1/ HC-DI-510a.2	Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption	Fresenius Group reports on impacts from legal proceedings in the 2023 Group Annual Report, see Note 31: <b>Commitments and Contingencies</b> (pg. 327 f.)
	HC-MS-510a.2	Description of code of ethics governing interactions with health care professionals	Fresenius Code of Conduct: <a href="https://www.fresenius.com/sites/default/files/2022-01/FRS_Code_of_Conduct_ext.pdf">https://www.fresenius.com/sites/default/files/2022-01/FRS_Code_of_Conduct_ext.pdf</a>  Fresenius Group Non-financial Report 2023: Strategy and management > Stakeholders and partnerships > <b>Transparency in the healthcare sector</b> (pg. 111)